Baseline characteristics (n = 75)
| . | n . | % . |
|---|---|---|
| Age | ||
| Median (range) | 62 (40-76) | |
| Gender | ||
| Male | 58 | 77 |
| Female | 17 | 23 |
| Ann Arbor stage | ||
| I/II | 6 | 8 |
| III/IV | 69 | 92 |
| Performance status | ||
| 0 | 49 | 65 |
| 1 | 23 | 31 |
| 2 | 3 | 4 |
| MIPI score | ||
| Low risk | 28 | 41 |
| Intermediate risk | 26 | 38 |
| High risk | 15 | 22 |
| Unknown* | 6 | |
| B symptoms | ||
| Present | 17 | 23 |
| Absent | 57 | 77 |
| Unknown | 1 | |
| Lactate dehydrogenase | ||
| Elevated | 30 | 41 |
| Not elevated | 44 | 59 |
| Unknown | 1 | |
| Bone marrow involvement | ||
| Yes | 59 | 80 |
| No | 15 | 20 |
| Unknown | 1 | |
| White blood count (×1000), per mm3 | ||
| Median (range) | 7.2 (3.0-57.7) | |
| Unknown | 5 | |
| . | n . | % . |
|---|---|---|
| Age | ||
| Median (range) | 62 (40-76) | |
| Gender | ||
| Male | 58 | 77 |
| Female | 17 | 23 |
| Ann Arbor stage | ||
| I/II | 6 | 8 |
| III/IV | 69 | 92 |
| Performance status | ||
| 0 | 49 | 65 |
| 1 | 23 | 31 |
| 2 | 3 | 4 |
| MIPI score | ||
| Low risk | 28 | 41 |
| Intermediate risk | 26 | 38 |
| High risk | 15 | 22 |
| Unknown* | 6 | |
| B symptoms | ||
| Present | 17 | 23 |
| Absent | 57 | 77 |
| Unknown | 1 | |
| Lactate dehydrogenase | ||
| Elevated | 30 | 41 |
| Not elevated | 44 | 59 |
| Unknown | 1 | |
| Bone marrow involvement | ||
| Yes | 59 | 80 |
| No | 15 | 20 |
| Unknown | 1 | |
| White blood count (×1000), per mm3 | ||
| Median (range) | 7.2 (3.0-57.7) | |
| Unknown | 5 | |
Five patients had baseline white blood cell count missing and 1 patient had baseline lactate dehydrogenase missing; therefore, the MIPI score could not be calculated.